Latest Articles

Publication Date
Post-marketing safety profile of Myfembree in approved gynecologic indications: a disproportionality analysis based on the FAERS database.

Myfembree, a fixed-dose combination of relugolix, estradiol, and norethindrone acetate, is approved for premenopausal women with heavy menstrual bleeding associated with uterine fibroids and moderate to severe pain associated with …

Published: Sept. 24, 2026, midnight
Dyspareunia and heavy menstrual bleeding as clinical predictors of concomitant endometriosis in Inflammatory Bowel Disease: A multidisciplinary prospective study.

The association between Inflammatory Bowel Disease (IBD) and endometriosis is undefined.

Published: Aug. 24, 2026, midnight
Dual Intrauterine Device Placement for Refractory Endometriosis Pain in a Bicornuate Uterus: A Case Report.

A 27-year-old nulliparous woman presented with chronic pelvic pain (CPP) (8/10 on the Numerical Rating Scale (NRS)), dysmenorrhea, heavy menstrual bleeding (HMB), and a family history of endometriosis. She had …

Published: Aug. 17, 2026, midnight
Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review.

In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly widespread demand for effective long-term medical therapies. The objective of …

Published: Aug. 14, 2026, midnight
Cancer Risk Profile of the Levonorgestrel-Releasing Intrauterine Device: A Narrative Review.

Background/Objectives: The levonorgestrel-releasing intrauterine device (LNG-IUD) is widely used as a long-acting reversible contraceptive and as a therapeutic option for heavy menstrual bleeding, endometriosis, adenomyosis, and endometrial hyperplasia. Although its …

Published: July 23, 2026, midnight
Mesonephric-like adenocarcinoma as an unexpected histological result after fertility saving procedure for presumed adenomyosis: a case report.

We report an unexpected case of mesonephric-like adenocarcinoma initially treated as a diffuse adenomyosis in a patient presenting with primary infertility. The aim of this report is to raise clinical …

Published: June 5, 2026, midnight
Coexisting adenomyosis in endometriosis: Similar pain and quality of life, with longer bleeding and bowel symptoms-A comparative cross-sectional study.

To compare pain, menstrual flow, and quality of life (QoL) between women undergoing surgery for endometriosis only compared with women with endometriosis and coexisting adenomyosis.

Published: April 17, 2026, midnight
Clinical Efficacy of Dienogest for Symptomatic Adenomyosis.

Background: This study was conducted to assess whether medical treatment with dienogest (DNG) is effective in women with symptomatic adenomyosis. Methods: This single-center, retrospective study included patients with symptomatic adenomyosis …

Published: April 6, 2026, midnight
Free pelvic fluid detection and quantification using transvaginal ultrasound: a surrogate marker for retrograde menstruation.

Can transvaginal ultrasonography (TVUS) reliably detect and quantify free pelvic fluid (FPF) as a surrogate marker of retrograde menstruation, and how do its volume and characteristics vary across menstrual phases, …

Published: March 1, 2026, midnight
Vaginal Contraception With NuvaRing Decreases Symptoms and Uterine Features of Adenomyosis: A Prospective Evaluation.

(Abstracted from Contraception 2025:150:111016, doi:10.1016/j.contraception.2025.111016) Adenomyosis occurs when ectopic endometrial glands invade the myometrium and can cause symptoms such as an enlarged uterus, heavy menstrual bleeding, pelvic pain, infertility, and …

Published: Dec. 31, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!